ulcerative colitis pipeline

View All

etrasimod-for-ulcerative-colitis-treatment
New Player in Ulcerative Colitis Treatment: Pfizer’s Etrasimod Entry Counters BMS’ Zeposia

Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III resul...

Find More

emerging-ulcerative-colitis-treatment-options
How the Novel Emerging Therapies Will Reshuffle the Ulcerative Colitis Treatment Dynamics?

Almost two decades ago, there were limited options for ulcerative colitis treatment. The readily available ulcerative colitis therapies were aminosalicylates and immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), with biologics (Adalimumab, Golimumab, infliximab, Ustekinumab, and Vedolizumab) rese...

Find More